Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This is a multi-centre, randomised, double blind, placebo controlled study on participants
with Motoric Cognitive Risk Syndrome to evaluate the efficacy and safety of Ginkgo Leaf
Extract and Armillariella Mellea Powder Oral Solution.